AU2022416432A1 - Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide - Google Patents

Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide Download PDF

Info

Publication number
AU2022416432A1
AU2022416432A1 AU2022416432A AU2022416432A AU2022416432A1 AU 2022416432 A1 AU2022416432 A1 AU 2022416432A1 AU 2022416432 A AU2022416432 A AU 2022416432A AU 2022416432 A AU2022416432 A AU 2022416432A AU 2022416432 A1 AU2022416432 A1 AU 2022416432A1
Authority
AU
Australia
Prior art keywords
oea
liver
composition
aquacelle
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022416432A
Other languages
English (en)
Inventor
Lin Lin
Daniele Piomelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2022416432A1 publication Critical patent/AU2022416432A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022416432A 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide Pending AU2022416432A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265314P 2021-12-13 2021-12-13
US63/265,314 2021-12-13
PCT/US2022/081372 WO2023114722A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Publications (1)

Publication Number Publication Date
AU2022416432A1 true AU2022416432A1 (en) 2024-07-25

Family

ID=86773562

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022416432A Pending AU2022416432A1 (en) 2021-12-13 2022-12-12 Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide

Country Status (8)

Country Link
US (1) US20250041249A1 (enExample)
EP (1) EP4447950A1 (enExample)
JP (1) JP2025500841A (enExample)
KR (1) KR20240134319A (enExample)
CN (1) CN118900687A (enExample)
AU (1) AU2022416432A1 (enExample)
CA (1) CA3242396A1 (enExample)
WO (1) WO2023114722A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4573920A1 (en) * 2023-12-22 2025-06-25 Centre National de la Recherche Scientifique Texturizing complex comprising oleoylethanolamide and at least one fatty substance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579413A (zh) * 2011-01-14 2012-07-18 傅瑾 油酰乙醇胺及其衍生物的新用途
WO2018187849A1 (en) * 2017-04-13 2018-10-18 Pharmako Biotechnologies Pty Limited Cold-water-dispersible chemical delivery system
US10702487B2 (en) * 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity

Also Published As

Publication number Publication date
US20250041249A1 (en) 2025-02-06
KR20240134319A (ko) 2024-09-09
CA3242396A1 (en) 2023-06-22
JP2025500841A (ja) 2025-01-15
CN118900687A (zh) 2024-11-05
WO2023114722A1 (en) 2023-06-22
EP4447950A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
de Paiva et al. Semaglutide attenuates anxious and depressive-like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the microbiota-gut-brain axis
Murakami et al. Recent advances in drug therapy for Parkinson's disease
JP7378402B2 (ja) カンナビノイドを含む放出調節組成物
CN111757729B (zh) 包含大麻素的改性释放组合物
Brierley et al. Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol
Iwai et al. Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice
RU2743075C2 (ru) Способы применения агонистов fxr
Mantovani et al. Cancer cachexia: medical management
Palafox-Sánchez et al. The interaction between brain and liver regulates lipid metabolism in the TBI pathology
Suguro et al. Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism
US20210069103A1 (en) Oral cannabinoid compositions and methods for treating neuropathic pain
TW202327589A (zh) 肝病之組合療法
Teixeira et al. Purple grumixama anthocyanins (Eugenia brasiliensis Lam.) attenuate obesity and insulin resistance in high-fat diet mice
CA2593982A1 (en) Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof
US20250041249A1 (en) Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
Liu et al. Quercetin attenuates atherosclerosis via modulating apelin signaling pathway based on plasma metabolomics
Lin et al. Diet-induced obesity disrupts histamine-dependent oleoylethanolamide signaling in the mouse liver
Lutkewitte et al. Hepatic monoacylglycerol acyltransferase 1 is induced by prolonged food deprivation to modulate the hepatic fasting response [S]
Goon et al. Untargeted serum metabolites profiling in high-fat diet mice supplemented with enhanced palm tocotrienol-rich fraction using UHPLC-MS
Ho et al. Mixed active metabolites of the SNP-6 series of novel compounds mitigate metabolic dysfunction-associated steatohepatitis and fibrosis: promising results from pre-clinical and clinical trials
Chen et al. Coconut oil derived medium-chain triglycerides ameliorated memory deficits via promoting neurite outgrowth and maintaining gut homeostasis in 5× FAD mice
US20080207745A1 (en) Orally-absorbed formulation for paromomycin
Wang et al. Berberine Ameliorates Atherosclerosis by Promoting Mitochondrial Biogenesis via SIRT1/PGC-1 α Signaling Pathway
Bagheri Cyclodextrins as a suitable carrier for the induction of feeding and analgesia by Delta-9 THC: a preclinical study in the female rat
Wang et al. Effects of Corn oligopeptide on Dexamethasone-induced muscle atrophy in Sprague-Dawley rats